Accolade Inc (NASDAQ:ACCD) stock surges 22.63% (As on January 9, 11:17:45 AM UTC-4, Source: Google Finance) after the company posted better than expected returns for the third quarter of FY 24. Net Loss has decreased by 47% to $21.1 million in Q3 2024 from $39.9 million in Q3 2023. Adjusted EBITDA has improved by 55%, with a loss of $4.6 million in Q3 2024 compared to a loss of $10.2 million in Q3 2023. Adjusted Gross Profit rose by 10% to $46.0 million, with Adjusted Gross Margin increasing to 46.3%. Accolade Inc’s balance sheet reflects a solid financial position with $230.017 million in cash and cash equivalents. The company’s efforts in managing its operating expenses are evident, with a focus on optimizing product and technology, sales and marketing, and general and administrative costs. The condensed consolidated statements of cash flows indicate a net cash used in operating activities of $22.120 million for the nine months ended November 30, 2023. The company is closing the physician gap, improving access to care, and leveraging AI and other innovations to make the system work better for our employer customers, their employees and their families.

ACCD in the third quarter of FY 24 has reported the adjusted loss per share of 28 cents, beating the analysts’ estimates for the adjusted loss per share of 46 cents, according to Zacks Investment Research. The company had reported the adjusted revenue growth of 9 percent to $99.4 million in the third quarter of FY 24, beating the analysts’ estimates for revenue of $96.5 million.

Additionally, the company has entered into separate, privately negotiated transactions with certain holders of its outstanding 0.50% Convertible Senior Notes due 2026 (the “Notes”) to repurchase (the “Repurchases”) approximately $76.5 million aggregate principal amount of the Notes for an aggregate cash repurchase price of approximately $65.8 million.

For the current quarter ending in February, Accolade said it expects revenue in the range of $121.5 million to $125.5 million. For the fiscal fourth quarter ending February 29, 2024, ACCD expects Adjusted EBITDA to be between $16 million and $20 million.

The company expects full-year revenue in the range of $411 million to $415 million and Adjusted EBITDA between $(6) million and $(10) million.

For the fiscal year ending February 28, 2025, the company has affirmed preliminary revenue and Adjusted EBITDA guidance. Revenue growth is expected to be of approximately 20% and Adjusted EBITDA to be between 2% and 4% of revenue.